Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mAb114 single-arm intervention trial for Ebola virus disease
jRCTs031220564Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ansuvimab in Ebola virus disease (EVD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Mortality at day 28. Started Jun 2023; status: completed.
02
Drugs
ansuvimab
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on jRCTs031220564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220564.